Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




mNGS CSF Test Outperforms Traditional Microbiological Testing for Infectious Diseases

By LabMedica International staff writers
Posted on 27 Jun 2025

Traditional, targeted tests for pathogen identification offer a frustrating guessing game with too many tests and too few answers. More...

Identifying a pathogen is only the first part of the story. Knowing detailed information about the virus can signal to a physician whether a patient’s infection is linked to an outbreak, carries unusual risks, or requires a change in management, crucial information when treating a patient with serious infections. Now, new research shows that a metagenomic sequencing (mNGS) test can deliver broader, deeper pathogen identification as compared to traditional methods.

Delve Bio (Boston, MA, USA) has developed Delve Detect, which offers genomic testing of cerebrospinal fluid (CSF) for more than 68,000 pathogens with a 48-hour turnaround time. Delve Detect analyzes all nucleic acids in a sample – RNA and DNA – directly from the site of infection to accurately identify the pathogens present and deliver more comprehensive microbial analysis than conventional testing. This groundbreaking infectious disease test is also capable of viral subtyping for select pathogens from sequence data analyzed through its proprietary bioinformatics pipeline, Delve Decide. Data from more than 4,800 patients tested over seven years, representing the largest study of mNGS CSF testing, has shown that mNGS delivered the highest diagnostic yield of any test, directly identifying more pathogens than all other testing methods (culture, antigen testing, PCR) combined.

More recently, data from a comparative study of Delve Detect CSF with a traditional PCR-based meningitis/encephalitis (ME) panel was presented at the latest American Society for Microbiology (ASM) Microbe conference. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner.

“Delve Bio’s metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not deliver a diagnosis and speed is critical,” said Brad Murray, chief executive officer of Delve Bio. “We’re working to make this technology more widely available to neurologists, infectious disease physicians and laboratory teams so they can get patients the answers they need.”

Related Links:
Delve Bio


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Capillary Blood Collection Tube
IMPROMINI M3
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.